Webinar Deep Dive: Breaking the GLP-1 Cost Cycle

  • Webinar
  • GLP-1s

How is Noom Health breaking the GLP-1 cost cycle? Join Cody Fair, Noom’s Chief Commercial Officer, Jennifer Jones, Noom Health’s Clinical Solutions Director, and Chantell Sell, Senior Director, National Pharmacy Clinical Leader for Willis Tower Watson, as they break down the nation’s obesity crisis, and discuss how employers can broaden access to GLP-1s, regardless of an organization’s current coverage policies for obesity medications. In this webinar, you’ll learn about Noom Health’s two new tailored solutions that can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

Speakers

  • Cody Fair

    Chief Commercial Officer
    Noom

  • Jennifer Jones

    Clinical Solutions Director
    Noom

  • Chantell Sell

    Senior Director, National Pharmacy Clinical Leader
    Willis Tower Watson

Watch On-Demand Webinar

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • GLP-1s
  • December 11
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
Breaking the GLP-1 cost cycle graphic
  • White Paper
  • GLP-1s
  • December 11
  • 1 min read

Breaking the GLP-1 Cost Cycle

Noom’s Breaking the GLP-1 Cost Cycle white paper dives into the scale of the obesity crisis and how Noom’s two tailored solutions can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

By Noom Team
  • Blog
  • December 11
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO